18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes

Clinical Nuclear Medicine

Volumn 39, Issue 1, 2014, Pages

  Marzola, Maria Cristina ^a   Chondrogiannis, Sotirios ^a   Grassetto, Gaia ^a   Rampin, Lucia ^a   Maffione, Anna Margherita ^a   Ferretti, Alice ^a   Opocher, Giuseppe ^b,c   Schiavi, Francesca ^c   Colletti, Patrick M ^d   Rubello, Domenico ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

18F DOPA PET CT; Paraganglioma; SDH; Succinate dehydrogenase

Indexed keywords

6 FLUORODOPA F 18; CATECHOLAMINE; SUCCINATE DEHYDROGENASE; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CHEMICAL ANALYSIS; CLINICAL ARTICLE; COMPLEX II DEFICIENCY; CYTOLOGY; FEMALE; FOLLOW UP; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; PARAGANGLIOMA; PET-CT SCANNER; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; YOUNG ADULT; ADRENAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; ENZYMOLOGY; GENETICS; MULTIMODAL IMAGING; MUTATION;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; MUTATION; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SUCCINATE DEHYDROGENASE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84891556013     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31829aface     Document Type: Article

References (49)

1. Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, et al. Clinical aspects of SDHx-related pheocromocytoma and paraganglioma. Endocr Relat Cancer. 2009;16:391-400
2. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287: 848-851
3. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268-270
4. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69:49-54
5. Opocher G, Schiavi F. Functional consequences of succinate dehydrogenase mutations. Endocr Pract. 2011;17:64-71
6. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet. 2001;69:1186-1197
7. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab. 2002;87:4771-4774
8. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-Alpha prolyl hydroxylase. Cancer Cell. 2005;7:77-85
9. Gottlieb E, Tomlinson IP Mitochondrial tumour suppressors: A genetic and biochemical update. Nat Rev Cancer. 2005;5:857-866
10. Young AL, Baysal BE, Deb A, et al. Familial malignant catecholaminesecreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab. 2002;87: 4101-4105
11. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943-951
12. Benn DE, Gimenez-Roqueplo AP, Reilly Jr. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91:827-836
13. Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with SDHB-Associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007;92:779-786
14. Adler JT, Meyer-Rochow GY, Chen H, et al. Pheochromocytoma: Current approaches and future directions. Oncologist. 2008;13:779-793
15. Schiavi F, Boedeker CC, Bausch BT, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA. 2005;294:2057-2063
16. Mannelli M, Ercolino T, Giache V, et al. Genetic screening for pheochromocytoma: Should SDHC analysis be included? J Medical Genet. 2007;44: 586-587
17. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: Which test is best? JAMA. 2002;287:1427-1434
18. Eisenhofer G, Lenders JW, Goldstein DS, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem. 2005;51:735-744
19. Bonnet S, Durand X, Baton O, et al. Malignant hereditary paraganglioma: Problems raised by non-functional forms management. Ann Chir. 2006;131: 626-630
20. Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: Clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210-5216
21. Maurea S, Cuocolo A, Reynolds JC, et al. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med. 1996;40:365-371
22. Jacques AE, Sahdev A, Sandrasagara M, et al. Adrenal pheochromocytoma: Correlation of MRI appearances with histology and function. Eur Radiol. 2008;18:2885-2892
23. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumours. Semin Nucl Med. 2006;36:228-247
24. Shapiro B, Copp JE, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma : Experience in 400 cases. J Nucl Med. 1985;26:576-585
25. Rufini V, Shulkin B. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications. Q J Nucl Med Mol Imaging. 2008; 52:341-350
26. Wiseman GA, Pacak K, O'Dorisio MS, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of paraganglioma: Results from a prospective multicenter trial. J Nucl Med. 2009;50:1448-1454
27. Havekes B, King K, Lai EW, et al. New imaging approaches to pheocromocytomas and paragangliomas. Clin Endocrinol. 2010;72:137-145
28. Bhatia KS, Ismail MM, Sahdev A, et al. (123)I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-Adrenal pheocromo cytomas : CT and MRI correlation. Clin Endocrinol. 2008;69:181-188
29. Milardovic R, Corssmit EP, Stokkel M. Value of 123I-MIBG scintigraphy in paraganglioma. Neuroendocrinol. 2010;91:94-100
30. King KS, Chen CC, Alexopoulos DK, et al. Functional imaging of SDHx-related head and neck paragangliomas: Comparison of 18F- fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779-2785
31. van der Harst E, de Herder WW, Bruining HA, et al. [(123)I]metaiodo benzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685-693
32. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86: 895-902
33. Chen L, Li F, Zhuang H, et al. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma. J Nucl Med. 2009;50:397-400
34. Chen L, Li F, Zhuang H, et al. Cardiac pheochromocytomas detected by Tc-99m-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) scintigraphy. Clin Nucl Med. 2007;32:182-185
35. Fiebrich HB, Brouwers AH, Kerstens MN, et al. 6-[F-18]Fluoro- Ldihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922-3930
36. Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-LDOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757-4767
37. Mackenzie IS, Gurnell M, Balan KK, et al. The use of 18- fluorodihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol. 2007;157:533-537
38. Fottner C, Helisch A, Anlauf M, et al. 6-18F-fluoro-L- dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: Correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010 95:2800-2810
39. Chondrogiannis S, Grassetto G, Marzola MC, et al. 18F-DOPA PET/CT biodistribution considerations in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun. 2012;33:179-184
40. Grassetto G, Massaro A, Cittadin S, et al. Kinetic of 18FDOPA in basal ganglia of non-human primate. Eur J Nucl Med Mol Imaging. 2009(suppl 2):145-539
41. Van Der Horst-Schrivers AN, Jager PL, Boezen HM, et al. Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomasV experience and meta-Analysis. Nucl Med Commun. 2012;33:179-184
42. TaBeb D, Sebag F, Hubbard JG, et al. Does iodine-131 metaiodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma? Clin Endocrinol. 2004;61:102-108
43. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-Associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262-2269
44. Treglia G, Cocciolillo F, de Waure C, et al. Diagnostic performance of 18Fdihydroxyphenylalanine positron emission tomography in patients with paraganglioma: A meta-Analysis. Eur J Nucl Med Mol Imaging. 2012;39:1144-1153
45. Brink I, Schaefer O, Walz M, et al. Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med. 2006;31:39-41
46. TaBeb D, Tessonnier L, Sebag F, et al. The role of 18F-FDOPA and 18F-FDGPET in the management of malignant and multifocal pheochromocytomas. Clin Endocrinol. 2008;69:580-586
47. Hoegerle S, Ghanem N, Altehoefer C, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003;30:689-694
48. Rischke HC, Benz MR, Wild D, et al. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. J NuclMed. 2012;53:1352-1358
49. Venkatesan AM, Trivedi H, Adams KT, et al. Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. Surgery. 2011;150:1186-1193